Form 8-K Amphastar Pharmaceutical For: Nov 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Piper Jaffray
November 9, 2017 7:52 AM ESTPiper Jaffray raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $19.00) while maintaining an Overweight rating.
Analyst David Amsellem notes solid performance from the base business. The analyst believes there is still room for meaningful value creation in the context of an EV/2018E EBITDA of 10x-11x.
... More


